Zealand Pharma A/S ZEAL
At closeSep 29, 2022, 4:00 PM EDT
52-week range unavailable
- Market cap
- 814.14M
- Revenue (ttm)
- 293.77M
- Shares out
- 46.12M
- Forward P/E
- -6.49
- Volume
- 2.16K
- Open
- 18.03
- Previous close
- 17.59
- Day's range
- 17.47 – 18.07
- Beta
- 1.34
- Analysts
- Buy
- Price target
- 32.30 (+83.6%)
- Earnings date
- Nov 10, 2022
2Y -14.48 (-45.15%)
Key statistics
- Enterprise value
- 434.86M
- PEG ratio
- 0.00
- Price / sales
- 2.77
- Price / book
- 1.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -22.40%
- Free cash flow
- -505.17M
- Total cash
- 864.44M
- Total debt
- 485.42M
- Return on equity
- -115.45%
- Short % of float
- 0.00%
- 50-day average
- 17.73
- 200-day average
- 15.57
Analyst view
Consensus: buy
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 10, 2022
Expected Nov 10, 2022. Consensus EPS estimate -0.71.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2022 | Sep 1, 2022 | -0.83 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.53 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -1.01 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -1.07 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -1.13 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.93 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 2022 | Needham | main | — | Buy |
| Nov 13, 2020 | Morgan Stanley | main | — | Overweight |
| Oct 13, 2020 | Morgan Stanley | main | — | Overweight |
| Aug 14, 2020 | Morgan Stanley | main | — | Overweight |
| Apr 15, 2020 | Morgan Stanley | main | — | Overweight |
| Mar 31, 2020 | Morgan Stanley | main | — | Overweight |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- zealandpharma.com
News
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 
Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration 
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases 
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes 
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) 
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts 
Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes 
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology 
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
Your note
Sign in to keep a note on ZEAL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Goldman Sachs Group Inc | 1.08% | 500,916 | 8.81M | Jun 29, 2022 |
| Farallon Capital Management Llc | 1.07% | 496,890 | 8.74M | Mar 30, 2022 |
| Bank of America Corporation | 0.47% | 220,523 | 3.88M | Jun 29, 2022 |
| AWM Investment Company, Inc. | 0.11% | 48,957 | 861.15K | Jun 29, 2022 |
| Jane Street Group, LLC | 0.05% | 23,976 | 421.74K | Jun 29, 2022 |
| Morgan Stanley | 0.01% | 6,705 | 117.94K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) International Discovery Fund | 2.85% | 1,326,807 | 23.34M | Mar 30, 2022 |
| iShares Core MSCI EAFE ETF | 0.43% | 200,193 | 3.52M | Aug 30, 2022 |
| iShares MSCI EAFE Small Cap ETF | 0.32% | 148,974 | 2.62M | Aug 30, 2022 |
| iShares Core MSCI Total International Stock ETF | 0.14% | 66,909 | 1.18M | Aug 30, 2022 |
| iShares MSCI Denmark ETF | 0.13% | 59,501 | 1.05M | Aug 30, 2022 |
| Hartford Healthcare Fund | 0.12% | 57,750 | 1.02M | Jan 30, 2022 |